673 related articles for article (PubMed ID: 29042366)
1. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Lenting PJ; Denis CV; Christophe OD
Blood; 2017 Dec; 130(23):2463-2468. PubMed ID: 29042366
[TBL] [Abstract][Full Text] [Related]
2. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
[TBL] [Abstract][Full Text] [Related]
3. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
Kitazawa T; Shima M
Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119
[TBL] [Abstract][Full Text] [Related]
4. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
[TBL] [Abstract][Full Text] [Related]
5. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
[TBL] [Abstract][Full Text] [Related]
6. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
Adamkewicz JI; Chen DC; Paz-Priel I
Thromb Haemost; 2019 Jul; 119(7):1084-1093. PubMed ID: 31064025
[TBL] [Abstract][Full Text] [Related]
7. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
[TBL] [Abstract][Full Text] [Related]
8. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
Yada K; Nogami K
Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1148-1154. PubMed ID: 32237902
[TBL] [Abstract][Full Text] [Related]
9. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
[TBL] [Abstract][Full Text] [Related]
10. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
Bowyer A; Kitchen S; Maclean R
Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
[TBL] [Abstract][Full Text] [Related]
11. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
[TBL] [Abstract][Full Text] [Related]
12. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
[TBL] [Abstract][Full Text] [Related]
13. Bispecific antibody mimicking factor VIII.
Nogami K
Thromb Res; 2016 May; 141 Suppl 2():S34-5. PubMed ID: 27207420
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG
Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400
[TBL] [Abstract][Full Text] [Related]
15. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
Díaz-Ricart M; Isola IM; Escolar G
Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
[TBL] [Abstract][Full Text] [Related]
16. A bispecific antibody demonstrates limited measurability in routine coagulation assays.
Hartmann R; Feenstra T; Knappe S; Schrenk G; Scheiflinger F; Dockal M
Blood Coagul Fibrinolysis; 2020 Sep; 31(6):353-365. PubMed ID: 32467424
[TBL] [Abstract][Full Text] [Related]
17. Emicizumab promotes factor Xa generation on endothelial cells.
Fager AM; Ellsworth P; Key NS; Monroe DM; Hoffman M
J Thromb Haemost; 2024 Jun; 22(6):1605-1615. PubMed ID: 38460838
[TBL] [Abstract][Full Text] [Related]
18. Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis.
Yada K; Nogami K; Ogiwara K; Shida Y; Furukawa S; Yaoi H; Takeyama M; Kasai R; Shima M
Int J Hematol; 2019 Oct; 110(4):419-430. PubMed ID: 31254165
[TBL] [Abstract][Full Text] [Related]
19. Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma.
Tripodi A; Chantarangkul V; Novembrino C; Scalambrino E; Boscolo-Anzoletti M; Clerici M; Rossi F; Peyvandi F
Clin Chem Lab Med; 2020 Sep; 59(2):365-371. PubMed ID: 32892172
[TBL] [Abstract][Full Text] [Related]
20. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.
Müller J; Pekrul I; Pötzsch B; Berning B; Oldenburg J; Spannagl M
Thromb Haemost; 2019 Sep; 119(9):1384-1393. PubMed ID: 31203578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
